DR. WASIF SHIRAZI M.D. NPI 1558336149

NPI Details

DR. Wasif Shirazi, M.D. is a hematology and oncology internal medicine in Tinley Park, IL with 30 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Wasif Shirazi, M.D. NPI is 1558336149. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

17333 LA GRANGE RD STE 200
TINLEY PARK, IL
ZIP 60487-510
Phone: (708) 342-1900
Fax: (708) 745-9993

The NPI 1558336149 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Unclassified drugs (HCPCS:J3490)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)

The enumeration date for this NPI number is 2/17/2006 and was last updated on 3/17/2018.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: